1 周健，吕虹，康熙雄. 中国汉族人群不同性别、年龄、体重指数之间细胞色素氧化酶cyp2c19基因多态性的检测 [J]. 中国临床药理学与治疗学，2007，12（2）：208-213.
2 Johnson J A，Cavallari L H. Warfarin pharmacogenetics [J]. Trends Cardiovasc Med，2015，25（1）：33-41.
3 Higashi M K，Veenstra D L，Kondo L M，et al. Association between cyp2c9 genetic variants and anticoagulation-related outcomes during warfarin therapy [J]. JAMA，2002，287（13）：1690-1698.
4 McDonald M G，Rieder M J，Nakano M，et al. Cyp4f2 is a vitamin k1 oxidase：An explanation for altered warfarin dose in carriers of the v433m variant [J]. Mol Pharmacol，2009，75（6）：1337-1346.
5 Singh O，Sandanaraj E，Subramanian K，et al. Influence of cyp4f2 rs2108622 （v433m） on warfarin dose requirement in asian patients [J]. Drug Metab Pharmacokinet，2011，26（2）：130-136.
6 Johnson J A，Caudle K E，Gong L，et al. Clinical pharmacogenetics implementation consortium （cpic） guideline for pharmacogenetics-guided warfarin dosing：2017 update [J]. Clin Pharmacol Ther，2017，102（3）：397-404.
7 冯频频，彭文星，石秀锦，等. 基因多态性对华法林剂量影响的研究进展 [J]. 中国药房，2017，28（11）：1581-1584.
8 Kimmel S E，French B，Kasner S E，et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing [J]. N Engl J Med，2013，369（24）：2283-2293.
9 Pirmohamed M，Burnside G，Eriksson N，et al. A randomized trial of genotype-guided dosing of warfarin [J]. N Engl J Med，2013，369（24）：2294-2303.
10 Harris K，Nguyen P，Van Cott E M. Platelet pla2 polymorphism and the risk for thrombosis in heparin-induced thrombocytopenia [J]. Am J Clin Pathol，2008，129（2）：282-286.
11 Gruel Y，Pouplard C，Lasne D，et al. The homozygous fcgammariiia-158v genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes [J]. Blood，2004，104（9）：2791-2793.
12 Cannon C P，Bhatt D L，Oldgren J，et al. Dual antithrombotic therapy with dabigatran after pci in atrial fibrillation [J]. N Engl J Med，2017，377（16）：1513-1524.
13 Pare G，Eriksson N，Lehr T，et al.Genetic determinants of dabigatran plasma levels and their relation to bleeding [J]. Circulation，2013，127（13）：1404-1412.
14 Zhang J H，Tang X F，Zhang Y，et al. Relationship between abcb1 polymorphisms，thromboelastography and risk of bleeding events in clopidogrel-treated patients with st-elevation myocardial infarction [J]. Thromb Res，2014，134（5）：970-975.
15 Spokoyny I，Barazangi N，Jaramillo V，et al. Reduced clopidogrel metabolism in a multiethnic population：Prevalence and rates of recurrent cerebrovascular events [J]. J Stroke Cerebrovasc Dis，2014，23（4）：694-698.
16 Yin T，Miyata T. Pharmacogenomics of clopidogrel：Evidence and perspectives [J]. Thromb Res，2011，128（4）：307-316.
17 Valgimigli M，Bueno H，Byrne R A，et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with eacts：The task force for dual antiplatelet therapy in coronary artery disease of the european society of cardiology （esc） and of the european association for cardio-thoracic surgery （eacts） [J]. Eur Heart J，2017，39（3）：213-260.
18 Serebruany V L，Cherepanov V，Kim M H，et al. Filing sources after oral p2y12 platelet inhibitors to the food and drug administration adverse event reporting system （faers） [J]. Cardiology，2017，138（4）：249-253.
19 Halvorsen S，Andreotti F，Ten Berg J M，et al. Aspirin therapy in primary cardiovascular disease prevention：A position paper of the european society of cardiology working group on thrombosis [J]. J Am Coll Cardiol，2014，64（3）：319-327.
20 Papp E，Havasi V，Bene J，et al. Glycoprotein iiia gene （pla） polymorphism and aspirin resistance：Is there any correlation? [J]. Ann Pharmacother，2005，39（6）：1013-1018.
21 Floyd CN，Ferro A. The pla1/a2 polymorphism of glycoprotein iiia in relation to efficacy of antiplatelet drugs：A systematic review and meta-analysis [J]. Br J Clin Pharmacol，2014，77（3）：446-457.
22 Wurtz M，Nissen P H，Grove E L，et al. Genetic determinants of on-aspirin platelet reactivity：Focus on the influence of pear1 [J]. PLoS One，2014，9（10）：e111816.
23 Maree A O，Curtin R J，Chubb A，et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin [J]. J Thromb Haemost，2005，3（10）：2340-2345.
24 Sharma V，Kaul S，Al-Hazzani A，et al. Association of cox-2 rs20417 with aspirin resistance [J]. J Thromb Thrombolysis，2013，35（1）：95-99.（下转247页）（上接336页）
25 Li Q，Chen B L，Ozdemir V，et al. Frequency of genetic polymorphisms of cox1，gpiiia and p2y1 in a chinese population and association with attenuated response to aspirin [J]. Pharmacogenomics，2007，8（6）：577-586.
26 Timur A A，Murugesan G，Zhang L，et al. P2ry1 and p2ry12 polymorphisms and on-aspirin platelet reactivity in patients with coronary artery disease [J]. Int J Lab Hematol，2012，34（5）：473-483.
27 Michelson A D，Furman M I，Goldschmidt-Clermont P，et al. Platelet gp iiia pl（a） polymorphisms display different sensitivities to agonists [J]. Circulation，2000，101（9）：1013-1018.
28 Wheeler G L，Braden G A，Bray P F，et al. Reduced inhibition by abciximab in platelets with the pla2 polymorphism [J]. Am Heart J，2002，143（1）：76-82.
29 Weber A A，Jacobs C，Meila D，et al. No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein iib/iiia inhibitors [J]. Pharmacogenetics，2002，12（7）：581-583.
30 Zhang G，Zhang Y，Ling Y，et al. Web resources for pharmacogenomics [J]. Genomics Proteomics Bioinformatics，2015，13（1）：51-54. |
